Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Generex announces FINRA approval of corporate action, payment of dividends » 09:22
02/24/20
02/24
09:22
02/24/20
09:22
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology announced that FINRA has officially posted the Generex 2:5 stock dividends in Generex and NuGenerex Immuno-Oncology to the FINRA web site, and the dividends will be paid on Monday, February 24, 2020. Remember that anyone who sells their shares before the market close on the ex-date of February 25th will lose the dividend, which will be transferred to the buyer of your shares. Joe Moscato, President & CEO of Generex, said, "I would like to extend my congratulations and sincere thanks to our valued shareholders, because we can now officially declare that the stock dividends will be paid on Monday the 24th as FINRA has posted the approval of our corporate action on their web site. I would like to thank all of you for your patience and support of Generex throughout this process, which has delayed our plans for five months. We realize this delay has eroded share value, however, with the dividend paid, we are now we are poised for growth and success. With the dividend being paid next week, and our Generex S-1 registration statement filed, we can now execute fully on our plans. As a first step next week, we will be filing an S-1 for the spin out of NuGenerex Immuno-Oncology, with goal of listing directly onto the Nasdaq. With the S-1 funding, our subsidiaries can increase manufacturing, sales & marketing, and distribution of our revenue generating products. Our subsidiaries MediSource and Pantheon are already delivering sales growth of nearly 400% year over year, and we can now scale manufacturing to expand this growth. As Excellagen continues to gain approval from VAC committees in the VA system, we can expand the Olaregen sales force and implement our product line extension with Excellagen Aesthetics into the aesthetic dermatology market. We will turn on our public company MSO for orthopedic surgeons and podiatrists, and we will build NuGenerex Health in Arizona to deliver an integrated, multi-disciplinary diabetes management solution with our physician partners and continuing our efforts in diabetes, we will close on our acquisition of ALTuCELL, which is initiating human clinical trials of implanted cellular therapy using Altucaps for the treatment of Type I diabetes. We are excited about our opportunities to deliver exceptional value to our shareholders in 2020 as we achieve the success that we envisioned when we took over the company three years ago."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Conference/Events
Generex to hold a conference call » 10:25
02/13/20
02/13
10:25
02/13/20
10:25
GNBT

Generex

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Moscato addresses the Coronavirus pandemic with Ii-Key Peptide Vaccines and provides a corporate update on a conference call to be held on February 13 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Generex to hold a conference call » 04:55
02/13/20
02/13
04:55
02/13/20
04:55
GNBT

Generex

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Moscato addresses the Coronavirus pandemic with Ii-Key Peptide Vaccines and provides a corporate update on a conference call to be held on February 13 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Generex to hold a conference call » 14:47
02/12/20
02/12
14:47
02/12/20
14:47
GNBT

Generex

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Moscato addresses the Coronavirus pandemic with Ii-Key Peptide Vaccines and provides a corporate update on a conference call to be held on February 13 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Generex declares new dividend record date of February 17 » 08:41
02/07/20
02/07
08:41
02/07/20
08:41
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology announced the successful completion of the FINRA review process for the dividend. After an exhaustive and long review, FINRA has determined that the original August 30 record date is too long ago to adequately track all the pay due bills from stock being bought and sold by investors, so a new record date of February 17th, 2020 has been established. This will insure everyone who has bought stock since August and retains the stock will receive the dividend not by way of a Pay Due Bill, but rather, directly from Generex. Those who sold stock after the original record date need not worry about anything as they were formally entitled to receive the dividend, but they would have had to transfer the dividend to the buyer of their shares. With the new February 17th record date being established, those who are entitled to receive the 5/2 stock dividend in Generex and the 5/2 stock dividend in NuGenerex Immuno-Oncology will receive it directly from the company. In addition, the pay date is now February 24th and ex-date is February 25th. If a shareholder sells the stock after the record date the pay due bill process will be in full effect and the shareholder will be required to transfer the dividend stock to the buyer. The ex-date rule in this situation is found in FINRA Rules Section 11140 (b)(2), which reads as follows: " In respect to cash dividends or distributions, stock dividends and/or splits, and the distribution of warrants, which are 25% or greater of the value of the subject security, the ex-dividend date shall be the first business day following the payable date."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Generex says NuGenerex subsidiaries working to address coronavirus » 08:26
02/06/20
02/06
08:26
02/06/20
08:26
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology announced that the company is working with third party groups and government agencies to reactivate the previously robust research and development to generate Ii-Key peptide vaccines against pandemic viruses. The patented NuGenerex Immuno-Oncology Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular, the Ii-Key ensures potent activation of CD4+ T cells, which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation while maintaining absolute specificity of response. The peptides and Ii-Key are made from naturally occurring amino acids, ensuring an excellent safety profile for Ii-Key peptide vaccines. Also, there are many companies with existing facilities that can make clinical-grade synthetic peptide vaccines in hundred-kilogram quantities, providing a scalable, economically feasible rapid-response vaccine to pandemic viruses; a kilogram of Ii-Key peptide vaccine would be enough to vaccinate roughly 1 million people. Unfortunately, when these pandemics fade out, everyone forgets about them until the next one. When the SARS scare waned, we focused all of our resources on developing Ii-Key immunotherapeutic peptide vaccines for cancer. Generex has been on the forefront of immunotherapy using our proprietary Ii-Key peptide vaccine technology. NGIO has extensive experience with the design of viral and cancer vaccines. We designed a series of vaccine peptides for the potentially pandemic H5N1 avian influenza virus that were tested in over 120 volunteers as part of a Phase I trial. The vaccine peptides were safe, well tolerated, and generated a specific immune response as designed. In addition to the H5N1 study, peptides with the same Ii-Key modification have been used in multiple clinical trials in patients with early stage cancer, including breast and prostate cancers. To date, all Ii-Key peptide vaccine studies demonstrated excellent safety as well as specific and long-lasting immune responses. Avian influenza has recently been identified in animals in Wuhan, China so the Ii-Key-H5N1 vaccine, with human safety data is ready to be deployed in the clinical setting to inoculate people against another potential pandemic. Based on our experience from the H5N1 virus Ii-Key peptide vaccine program, we have developed a strategy to design, screen and identify vaccine peptides to any novel pathogenic virus within 5 months, and we are initiating efforts to develop a vaccine against 2019-nCOV.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Conference/Events
Generex to host business news update conference call » 09:10
01/21/20
01/21
09:10
01/21/20
09:10
GNBT

Generex

$0.00 /

+ (+0.00%)

Conference call to…

Conference call to provide an update on the 2:5 Generex stock dividend, the 2:5 NuGenerex Immuno-Oncology (NGIO) stock dividend and the FINRA approval process will be held on January 21 at 9:30 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Generex's Olaregen announces introduction of Excellagen Aesthetics » 09:08
01/17/20
01/17
09:08
01/17/20
09:08
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology announced that their subsidiary, Olaregen Therapeutix, Inc., is introducing a new product, Excellagen Aesthetics for the cosmetic surgery and aesthetic dermatology market. FDA 510(k) cleared with an indication for the management of wounds, Excellagen Aesthetics is intended for use following facial rejuvenation procedures, including post-laser surgery, post-chemical peels, and post- skin ablation. Excellagen is a ready to use 3-dimensional wound conforming matrix that supports a favorable wound healing environment. It is designed to activate collagen, accelerate granulation, and promote new tissue growth by providing a structural scaffold for cellular migration and proliferation. Excellagen Aesthetics has been shown in vitro to trigger the localized release of endogenous growth factors including Platelet-Derived Growth Factor, a key biological mediator of wound healing. Olaregen is rolling out Excellagen Aesthetics with a dedicated contract sales force uniquely positioned in major metropolitan areas across the United States where the majority of aesthetic dermatology procedures are clustered.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Generex says previously announced dividends has been postponed » 08:24
01/10/20
01/10
08:24
01/10/20
08:24
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology announced that the pay day for the two previously announced dividends in Generex Biotechnology and in NuGenerex Immuno-Oncology have been postponed due to FINRA's continuing review and approval process. Since our last announcement, FINRA requested additional information, which Generex has supplied, but FINRA has not yet completed processing of this information. We are delaying announcing a new payment date and ex-dividend date until we have a firm estimated of the FINRA approval date, which we believe we will have sometime next week. Although unfortunate, the delay is temporary and Generex is committed to delivering the dividends to shareholders as soon as the approvals are obtained. Please remember if you sell your shares before the ex-date you will get a pay due bill and your dividend shares will go to the buyer. Conversely, if you buy shares up through the ex-date, you will receive the dividend through the "Pay Due" system and the seller will automatically pay you the dividends through broker to broker transfer. Joe Moscato, President & CEO of Generex said, "We are working closely with FINRA to answer any and all questions they have about the dividends, and we will provide an update on timing just as soon as possible." Mr. Moscato continued, "Personally, I cannot wait to finally pay this dividend that shareholders deserve for believing in our plans that we started 3 years ago on January 17, 2017. Once the dividend is paid, we can concentrate on building the enterprise value of the acquisitions we have made in the orthopedic and wound care space, launching our end-to-end solution for diabetes care in Arizona, bringing NuGenerex Immuno-Oncology public, and closing the ALTuCELL deal to initiate the clinical development of their cutting-edge cell therapy for Type I diabetes. Again, thanks for your patience and we are looking towards positive results for Generex and our NuGenerex family of subsidiary companies in 2020."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Generex says pay day for previously announced dividends has been delayed » 08:06
01/03/20
01/03
08:06
01/03/20
08:06
GNBT

Generex

$0.00 /

+ (+0.00%)

Generex Biotechnology…

Generex Biotechnology announced that the pay day for the two previously announced dividends in Generex Biotechnology and in NuGenerex Immuno-Oncology have been delayed due to the ongoing FINRA review and approval process. FINRA required a new approval process for the previously announced pay date, although the record date had not changed. Generex has provided FINRA with all requested information, and once FINRA approves and posts its approval to DTC, Generex will commence preparations for the dividend payment. Although unfortunate, the delay is temporary and Generex is committed to delivering the dividends to shareholders as soon as the approvals are obtained. Please remember if you sell your shares before the ex-date you will get a pay due bill and your dividend shares will go to the buyer. Conversely, if you buy shares up through the ex-date, you will receive the dividend through the "Pay Due" system and the seller will automatically pay you the dividends through broker to broker transfer. CEO Joe Moscato said, "I would like to thank all of our shareholders for your patience in this process. As a result of FINRA's continuing review of the revised dividend, and with the addition of the NuGenerex Immuno-Oncology stock dividend, the FINRA review process was delayed over the holiday. Having provided all documentation necessary, Generex is simply waiting on FINRA to post its approval with the DTC so that brokers are prepared to accept and record the dividend shares into shareholder accounts. As per guidance from regulators, we expect the approvals next week, so the new pay date for the long-awaited dividend will be January 10, 2020. We will notify shareholders as soon as we hear of the approval from FINRA. Personally, I cannot wait to finally pay this dividend that shareholders deserve for believing in our plans that we started 3 years ago on January 17, 2017. Once the dividend is paid, we can concentrate on building the enterprise value of the acquisitions we have made in the orthopedic and wound care space, launching our end-to-end solution for diabetes care in Arizona, bringing NuGenerex Immuno-Oncology public, and closing the ALTuCELL deal to initiate the clinical development of their cutting-edge cell therapy for Type I diabetes. Again, thanks for your patience and we are looking towards positive results for Generex and our NuGenerex family of subsidiary companies in 2020."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.